Wednesday, May 13, 2015

ASCO 2015 Abstracts Released - A few abstracts of trading interest

The highly anticipated ASCO abstract release happened at 2:00 PST today and here are some abstracts of trading interest.

Exelixis (EXEL) - Abstract 9006 reports updated Progression Free Survival for Roche partnered compound Cobimetinib in advanced BRAF-mutated melanoma.  Updated PFS came in at 12.3 months vs. 7.2 months for the control arm for a hazard ratio of .58.  In summary, this is great news and should add further ammunition for the upcoming FDA PDUFA date on August 11th.  I'd expect the stock to continue moving up when the results are formally released.

Oncothyreon (ONTY) - Abstracts 612 and 602 report Phase 1 results for lead compound ONT-380 in breast cancer.  I listened in on their first quarter call on Monday and the CEO made it a point to state that more mature data than than the initial abstract release will be presented at ASCO.  He's a pretty dry guy but his tone was that of excitement so my take is that the additional data will be positive.  Note that the stock was up 15% in after-hour trading tonight off the current data so who knows what will happen if better data is released at ASCO.

Array (ARRY) - There's a ton of abstracts and data released on their three late-stage wholly-owned and partnered compounds.  Some good and some bad but overall I think the data is positive and the stock will move up as investors sift through the data and press released hit the day of the presentations.

Threshold (THLD) - Abstracts presenting clinical data on both of the companies compounds, TH-302 and TH-4000, show clinical activity.  Further data will be presented at the conference so this one could move.

Ziopharm (ZIOP) - Abstract 7504 shows that compound Palifosfamide failed to improve overall survival in patients with lung cancer.  Though this was expected as prior trials in this compound failed, I'm short this stock and expect it could move lower on the news.

Immunomedics (IMMU) - Abstracts covering compounds IMMU-130, IMMU-132, and sacituzumab govitecan show various degrees of clinical activity in Phase 1 and 2 trials. I'd expect more detailed and mature data to be presented at the meeting which could move the stock up.

That's about it for now but will provide further updates as I sift through the thousands of abstracts. Good luck investing!

No comments:

Post a Comment

Thank you for your contribution to